Single administration of PRX302 as a short outpatient procedure provided
sustained benefit over 12 months
SAN DIEGO, CA and VANCOUVER, Oct. 9, 2012 /PRNewswire/ - Sophiris Bio Inc.
(TSX: SHS) today released top line data from the 12 month follow up of
patients receiving PRX302 for the treatment of benign prostatic
hyperplasia (BPH, or enlarged prostate) in a Phase 2b study (TRIUMPH).
PRX302 produced a clinically significant improvement in the subjective
symptom score (International Prostate Symptom Score, or IPSS) and the
objective measure of mean peak urinary flow rate (Qmax) sustained over
12 months. As previously reported, the trial met the primary clinical
endpoint of the study, which was to demonstrate the efficacy of PRX302
at 90 days post-treatment by a statistically significant improvement
from baseline in IPSS when compared to placebo (vehicle only
injection). Consistent with the results previously reported for this
study, PRX302 continued to be well tolerated with no erectile function
side effects during the 12 months following treatment.
PRX302 treatment resulted in approximately 8 to 9-point average
reduction of IPSS that was sustained over 12 months. The IPSS is a
patient self-administered questionnaire of lower urinary tract symptoms
with a possible range of 0 to 35 points, with 0 being no symptoms and
35 being the high end of severe symptoms. This average improvement in
IPSS was a clinically meaningful 2.8 to 4.1 point reduction over and
above the IPSS improvement observed in the placebo group. In addition,
PRX302 treatment resulted in a ~3 mL/sec average increase in Qmax,
which was sustained over 12 months. Both IPSS and Qmax are validated
clinical endpoints used for BPH product regulatory approvals.
PRX302 was well tolerated in this study with patients who had moderate
to severe lower urinary tract symptoms due to BPH, about half of whom
had previously taken oral medication for BPH. The side effect profile
was favorable with most of the side effects attributed to the injection
procedure itself and not related to drug toxicity.
"PRX302 is demonstrating potential as an alternative treatment to oral
medications as well as surgical procedures," said Randall Woods,
President and CEO of Sophiris Bio. "Patients commonly stop oral
medications for lack of efficacy or side effects, or are non-compliant
with taking daily pills. 'Minimally invasive' procedures that aim to
remove excess tissue in the prostate require anesthesia and
catheterization, which limit access for patients and add to cost.
PRX302 has the potential to be safer than surgical procedures, more
efficacious than oral medications, and with a sustained treatment
effect for 12 months."
Woods added: "We expect to confirm these results in a pivotal study that
closely resembles the design of this Phase 2b study and includes the
same proven clinical endpoints used for prior regulatory approvals of
drugs for BPH."
Benign prostatic hyperplasia (BPH) is an enlarged prostate gland often
resulting in a constricted or partially blocked urethra that can lead
to pain, discomfort and other complications with urination. BPH occurs
in almost all men as they age, with 50% of men over age 50 and 70% of
men over age 70 complaining of symptoms. If untreated, it can lead to
urinary problems such as:
Trouble starting and stopping urination
Frequent and irregular needs to urinate, particularly in the night while
A weak urine stream
Painful urination or urinary retention, leading to infections, stones or
In the US, approximately 11 million men have been diagnosed with BPH.
Five million of these patients are bothered enough by symptoms to seek
treatment, such as daily pharmaceuticals, but these treatments often
lack sustainable efficacy and are associated with undesirable side
effects including sexual dysfunction. With current pharmaceutical
treatments, symptoms will usually return if medication is discontinued.
More aggressive treatment options include invasive surgical procedures
that may be successful at treating BPH but may be accompanied by
operative complications. Any type of prostate surgery can cause side
effects, such as semen flowing backward into the bladder (retrograde
ejaculation), loss of bladder control (incontinence) and impotence
PRX302 is designed to be a once-a-year treatment for the long-term
relief of BPH symptoms without causing sexual dysfunction or
sacrificing quality of life. PRX302 is precisely targeted to the
prostate tissue constricting the urethra without damaging neighboring
healthy tissue. It is delivered by a 1-3 minute injection completed
during an office visit. PRX302 has been engineered to be activated
only by the prostate specific antigen (PSA) enzyme that is produced in
large amounts in the prostates of men with BPH. Once activated, PRX302
forms disruptive pores in the membranes of prostate cells, thus
creating a highly targeted, localized and more convenient approach to
eliminating prostate cells constricting the urethra.
Sophiris Bio Inc. is a urology company developing a late-stage, highly
targeted treatment for benign prostatic hyperplasia (BPH, or enlarged
prostate), an unsatisfied market with large potential demand. PRX302,
the company's lead candidate for BPH, is designed to be as efficacious
as pharmaceuticals, less invasive than the surgical interventions, and
without the sexual side effects seen with existing treatments. Sophiris
is advised by world-leading urologists, backed by experienced
investors, and led by a team that has achieved more than twenty drug
approvals including drugs with annual sales in excess of $1 billion.
For more information, please visit www.sophirisbio.com.
Certain statements included in this press release may be considered
forward-looking, including statements about the potential for PRX302.
Such statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking
statements are based on Sophiris' current beliefs as well as
assumptions made by and information currently available to Sophiris and
relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties inherent in late stage drug
development and risks relating to obtaining FDA and other regulatory
approvals as well as risks identified by Sophiris in its public
securities filings; actual events may differ materially from current
expectations. Sophiris disclaims any intention or obligation to update
or revise any forward-looking statements in this press release, whether
as a result of new information, future events or otherwise.
SOURCE Sophiris Bio, Inc.